Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8663677 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL19604963 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL4942567 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL6378123 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL1679629 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL11390770 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL17320713 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL20145736 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL8892986 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL11390785 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300143-A | Water soluble dye, sulfone, and amide or cyclic amine | XEROX CORPORATION (US) | 1994-04-05 | — | — | US | claimed |
| US-11963527-B2 | Compounds, compositions, and methods for altering insect and organism behavior | BASF CORPORATION (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-9783545-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| CN-103396348-A | Rorifone derivatives and applications to preparing anticancer medicaments | KUNMING LONGJIN PHARMACEUTICAL CO LTD | 2013-11-20 | — | — | CN | disclosed |
| EP-0602914-B1 | Ink compositions for ink jet printing | XEROX CORP (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0602914-A1 | Ink compositions for ink jet printing | XEROX CORPORATION (US) | 1994-06-22 | — | — | EP | disclosed |
| US-5300143-A | Water soluble dye, sulfone, and amide or cyclic amine | XEROX CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963527-B2 | Compounds, compositions, and methods for altering insect and organism behavior | ACHE, DDT, MGLL | FAAH 148/4885CA2 3330/4885TSHR 2908/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | FAAH 2023/4885CA2 2333/4885TSHR 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.